(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/205012 A1

(51) International Patent Classification:
C12N 15/115 (2010.01) *A61K 31/713* (2006.01)

(21) International Application Number:
PCT/EP2021/059328

(22) International Filing Date:
09 April 2021 (09.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

20168929.6	09 April 2020 (09.04.2020)	EP
20176023.8	22 May 2020 (22.05.2020)	EP
20180781.5	18 June 2020 (18.06.2020)	EP
20204036.6	27 October 2020 (27.10.2020)	EP

(71) Applicant: **BERLIN CURES GMBH** [DE/DE]; Knesebeckstraße 59-61, 10719 Berlin (DE).

(72) Inventors: **HABERLAND, Annekathrin**; Streustr. 43, 13086 Berlin (DE). **MÜLLER, Johannes**; Güntzelstr. 63, 10717 Berlin (DE). **WALLUKAT, Gerd**; Wolkensteinstr. 4, 13129 Berlin (DE). **GÖTTEL, Peter**; Schwarzwildweg 6, 14612 Falkensee (DE).

(74) Agent: **LAHRTZ, Fritz**; Patentanwälte Isenbruck Bösl Hörschler PartG mbB, Prinzregentenstr. 68, 81675 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

(54) Title: APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS




Figure 3

(57) Abstract: The present invention relates to new aptamer molecules for use in therapy of infections caused by viruses from the *Coronaviridae* family, a method of preventing infection caused by viruses from the *Coronaviridae* family *in vitro/ex vivo*, a pharmaceutical composition and a kit comprising such aptamer molecules, and the use of aptamer molecules for preventing infection of somatic cells with a virus from the *Coronaviridae* family. The present invention also relates to affinity molecules binding to specific and newly identified epitopes of a key enzyme of *Coronaviridae* viruses.

WO 2021/205012 A1

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*